Core Insights - Chromosome karyotype analysis is the gold standard core technology in genetic disease diagnosis, prenatal screening and diagnosis, infertility cause investigation, blood system malignancy classification, and genetic testing of solid tumors, demonstrating irreplaceable clinical value [1][7] - The demand for prenatal diagnosis is steadily increasing due to the widespread adoption of the concept of optimal childbirth, the continuous expansion of the advanced maternal age population, and the ongoing standardization of marriage and pregnancy check-up processes [1][7] - The market size for chromosome karyotype analysis systems in China is projected to reach 196.7 million yuan by 2025, with a year-on-year growth of 18.6% [1][7] Overview - Chromosome karyotype analysis involves pairing, numbering, and grouping chromosomes based on specific morphological characteristics, and the karyotype analysis system integrates optical microscopy, computer image processing, AI algorithms, and digital storage for chromosome identification and analysis [2][3] - The system automates and standardizes chromosome analysis, replacing traditional manual methods, and is primarily applied in genetic disease diagnosis, prenatal diagnosis, tumor genetics research, and species identification [2][3] Market Policies - The chromosome karyotype analysis system is classified as a Class III medical device, and the medical device industry is a strategic emerging industry with strong growth potential, playing a crucial role in implementing the "Healthy China" strategy [4][5] Industry Chain - The upstream of the chromosome karyotype analysis system industry includes suppliers of high-magnification optical microscopes, fluorescence microscopes, and other hardware, while the downstream encompasses applications in reproductive health, blood malignancies, and research [6] - Reproductive health is the core demand market for chromosome karyotype analysis systems in China, projected to account for over 80% by 2025, with key applications in prenatal diagnosis centers and reproductive centers [6] Competitive Landscape - The market is characterized by international giants dominating the high-end market, while domestic leading enterprises are accelerating their replacement of imported products, with companies like Leica and Thermo Fisher leading in high-end systems [8] - Domestic companies such as Hangzhou Deshi Biotechnology Co., Ltd. are gaining market recognition through continuous AI algorithm iteration and localization, establishing a competitive advantage in both mid-range and high-end markets [8][9] Development Trends - Future advancements will see the integration of AI and deep learning technologies into chromosome karyotype analysis systems, automating the entire process and enhancing the ability to identify complex karyotype abnormalities [12] - The application fields will expand beyond traditional areas to include reproductive health, solid tumor auxiliary diagnosis, and occupational disease prevention, with a focus on enhancing capabilities in grassroots medical institutions [13] - Domestic enterprises will increase investment in core technology R&D, aiming to break the market monopoly of imported brands, while the industry may experience consolidation, leading to a higher concentration of leading enterprises [14]

Group 1 - The China Securities Regulatory Commission has issued a notice regarding the overseas issuance and domestic unlisted shares "full circulation" registration for Hangzhou Deshi Biotechnology Co., Ltd. [1] - Deshi Biotechnology plans to issue no more than 31.04 million overseas listed ordinary shares and will list on the Hong Kong Stock Exchange [1] - A total of 27 shareholders of the company intend to convert their combined 80.88 million domestic unlisted shares into overseas listed shares for circulation on the Hong Kong Stock Exchange [1] Group 2 - Deshi Biotechnology is a leading enterprise in the field of medical imaging AI and medical imaging equipment, with a global market presence [2] - The company has developed a diversified matrix of intelligent equipment and supporting products based on its self-developed general medical imaging base model iMedImage™, including systems for chromosome karyotype analysis and automatic cell imaging [2] - In 2024, Deshi Biotechnology achieved a market share of 30.6% in the chromosome karyotype analysis field in China, ranking first and breaking the long-standing monopoly of imported brands [2] - The company has established a customer base covering over 400 medical care centers and institutions nationwide, gaining widespread market recognition [2] - In 2025, Deshi Biotechnology was selected for the 11th batch of the "Excellent Domestic Medical Equipment Product Catalog" due to its technological innovation and clinical value [2] - The company aims to continue providing standardized intelligent imaging equipment, model-as-a-service (MaaS) cloud platforms, and localized self-training solutions to enhance the efficiency, accuracy, and accessibility of medical imaging diagnosis [2]